OFFICEFIRST Immobilien AG / Key word(s): IPO 10.10.2016 23:06 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- OFFICEFIRST Immobilien AG Bonn Ad hoc Release pursuant to Art. 17 para. 1 MAR NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE. OFFICEFIRST Immobilien AG: planned IPO postponed Bonn, October 10, 2016 - OFFICEFIRST Immobilien AG and its sole shareholder, IVG Immobilien AG, have decided to postpone the planned initial public offering ("IPO") of OFFICEFIRST Immobilien AG due to negative market developments, in particular in the real estate sector since the commencement of the marketing period at the beginning of last week. This decision was taken despite generally very positive feedback received throughout investor meetings with regard to OFFICEFIRST groups business model and real estate portfolio. The listing of the shares on the Prime Standard of the regulated market of the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) was originally planned for October 14, 2016. OFFICEFIRST Immobilien AG and IVG Immobilien AG will continue to evaluate the market environment regarding a potential IPO in the future. Bonn, October 10, 2016 OFFICEFIRST Immobilien AG Disclosing person: Mr. Libor Vincent Head of Communications & Investor Relations T: +49 69 60 60 50 13 62 F: +49 69 60 60 50 23 62 M: +49 162 44 94 90 6 E: libor.vincent@officefirst.com Important notice These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Securities") of OFFICEFIRST Immobilien AG (the "Company") in the United States, Germany or any other jurisdiction. The Securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Securities of the Company have not been, and will not be, registered under the Securities Act. Any sale in the United States of the Securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in, and in reliance on, Rule 144A under the Securities Act. This publication constitutes neither an offer to sell nor a solicitation to buy the Securities of the Company. The offer will be made solely by means of, and on the basis of, the published securities prospectus (including potential supplements). An investment decision regarding the publicly offered securities of OFFICEFIRST Immobilien AG should only be made on the basis of the securities prospectus (including potential supplements). The securities prospectus (including potential supplements) is available free of charge from OFFICEFIRST Immobilien AG, Mozartstr. 4-10, 53115 Bonn, Germany, or on the OFFICEFIRST Immobilien AG website. In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. The Underwriters are acting exclusively for the Company and the Selling Shareholder and no-one else in connection with the Offering. They will not regard any other person as their respective clients in relation to the Offering and will not be responsible to anyone other than the Company and the Selling Shareholder for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offering, the contents of this announcement or any other matter referred to herein. In connection with the Offering, the Underwriters and any of their affiliates, acting as investors for their own accounts, may subscribe for or purchase securities of the Company and may otherwise deal for their own accounts. Accordingly, references in the Prospectus to the securities being issued should be read as including any issue or offer to the Underwriters and any of their affiliates acting as investors for their own accounts. In addition certain of the Underwriters or their respective affiliates may enter into financing arrangements and swaps with investors in connection with which such Underwriters (or their affiliates) may from time to time acquire, hold or dispose of the Company's shares. The Underwriters do not intend to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so. None of the Underwriters or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or, with limited exception, other information relating to the Company the Selling Shareholder, or their respective subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. 10.10.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: OFFICEFIRST Immobilien AG Mozartstraße 4-10 53115 Bonn Germany Phone: Fax: E-mail: info@officefirst.com Internet: www.officefirst.com WKN: Listed: Regulated Market in Frankfurt (Prime Standard) End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: OFFICEFIRST Immobilien AG: planned IPO
Top 10 Most Recent News Articles
AI Drives Major Time Savings in Endoscopy Tech
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
NARUTO Card Game Set for June 2027 Global Launch
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue ReadingTop 5 Most Recently Viewed Articles
Discovering High-Yield Dividend Opportunities Today
Ares Capital got traders buzzing back when it offered a solid yield of around 9%. It stood out as the largest publicly traded business development company (BDC) globally, which made income-focused investors take notice. But here’s the kicker: BDCs like Ares can sidestep corporate taxes if they hand out most of their earnings as dividends, creating a prime hunting ground...
Continue Reading
Anthony DiSilvestro Joins Keurig Dr Pepper as CFO
Keurig Dr Pepper Welcomes New Chief Financial Officer Keurig Dr Pepper (NASDAQ: KDP) recently announced an exciting leadership change with the appointment of Anthony DiSilvestro as its new Chief Financial Officer. This important transition marks a significant step as DiSilvestro steps into his role immediately, bringing over four decades of extensive experience across...
Continue Reading
Elisa's New Branding: Introducing Elisa Industriq for Growth
Elisa Unveils Elisa Industriq: A New Era in Software Solutions Elisa Oyj is excited to announce a significant milestone as it consolidates its international digital services under a unified brand known as Elisa Industriq. This initiative aims to streamline its software offerings and create a robust identity within the market. Following this change, Elisa will report the...
Continue Reading
Illinois American Water Backs United Way with Grants
Driving Community Support Through Strategic Grants The American Water Charitable Foundation and Illinois American Water are making waves by putting their money where their mouth is, delivering a batch of state strategic impact grants to United Way organizations that promise to spark some serious change. It’s not every day you see such a duo diving into local communities...
Continue Reading
Essity Faces Early Bond Repayment Demand Amid Dispute
Essity Faces Early Bond Repayment Demand Amid Dispute Essity has found itself in a challenging situation. Recently, a handful of bondholders have made a demand for the early repayment of bonds that are set to mature in the upcoming years of 2029, 2030, and 2031. This unexpected request has prompted Essity to reaffirm its position and contest the claims of these...
Continue Reading